NCT06844292 Evaluation of Microinvasive Glaucoma Surgery: MINIject® Versus Hydrus® Microstent in Combination With Cataract Surgery
| NCT ID | NCT06844292 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Graz |
| Condition | Glaucoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 152 participants |
| Start Date | 2025-03-03 |
| Primary Completion | 2027-03-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 152 participants in total. It began in 2025-03-03 with a primary completion date of 2027-03-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to investigate postoperative outcomes after two different MIGS implants (MINIject or Hydrus) in combination with cataract surgery for patients with glaucoma.
Eligibility Criteria
Inclusion Criteria: * Patients with glaucoma in which surgery is indicated to reach target intraocular pressure as well as lens opacities where CS is indicated * Clinically eligible for both surgeries * Subjects not anticipated to require any further surgery in the next 12 months * Patients' age \> 18 years Exclusion Criteria: * Patients who do not want to make follow-ups at the department * Angle closure, uveitic, neovascular, congenital glaucoma, iridocorneal endothelial syndrome, Axenfeld-Rieger syndrome * Prior filtering glaucoma surgery, suprachoroidal stent, retinal surgery, corneal graft surgery or cyclophotocoagulation * Allergy to any drugs or substances required for the protocol * Pregnant women
Contact & Investigator
Ewald Lindner, Prof.
PRINCIPAL INVESTIGATOR
Medical University of Graz
Frequently Asked Questions
Who can join the NCT06844292 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06844292 currently recruiting?
Yes, NCT06844292 is actively recruiting participants. Contact the research team at ewald.lindner@medunigraz.at for enrollment information.
Where is the NCT06844292 trial being conducted?
This trial is being conducted at Graz, Austria.
Who is sponsoring the NCT06844292 clinical trial?
NCT06844292 is sponsored by Medical University of Graz. The principal investigator is Ewald Lindner, Prof. at Medical University of Graz. The trial plans to enroll 152 participants.